前交叉韧带重建中软组织同种异体移植物较自体移植物增加翻修风险:移植物处理方式与时间因素的作用
基于Kaiser Permanente ACLR登记的前瞻性队列研究,纳入14,015例前交叉韧带重建病例,比较骨-髌腱-骨自体、腘绳肌自体与软组织同种异体移植物的无菌性翻修风险。调整年龄、性别和种族后,经≥1.8 Mrad辐照(含或不含化学处理)及BioCleanse处理的同种异体移植物翻修风险高于腘绳肌自体移植物,未处理同种异体移植物与自体移植物相比翻修风险无差异。同种异体移植物的处理和术后时间影响翻修风险。
要点
- 与腘绳肌自体移植物相比,≥1.8 Mrad辐照(含或不含化学处理)及BioCleanse处理同种异体移植物翻修风险更高。
- 未处理同种异体移植物及<1.8 Mrad辐照(含或不含化学处理)移植物与腘绳肌自体移植物相比翻修风险无差异。
- 与骨-髌腱-骨自体移植物相比,腘绳肌自体及多种处理同种异体移植物翻修风险更高,未处理同种异体移植物无差异。
核心结论
- 使用软组织同种异体移植物行前交叉韧带重建时,移植物处理和术后时间影响翻修风险。
- 组织处理显著影响翻修手术风险,处理程度越高风险越明显,且随随访时间延长而增加。
- 外科医生和患者需知晓前交叉韧带重建所用各种软组织同种异体移植物的翻修风险增加。
研究设计与样本
- 队列研究,证据等级2级。
- 使用Kaiser Permanente ACLR登记前瞻性收集的前交叉韧带重建病例,纳入14,015例,其中男性8,924例(63.7%),白人6,397例(45.6%)。
- 骨-髌腱-骨自体移植物4,557例(32.5%),软组织同种异体移植物3,751例(26.8%),腘绳肌自体移植物5,707例(40.7%)。
- 软组织同种异体移植物中位年龄34.6岁,腘绳肌自体移植物24.3岁,骨-髌腱-骨自体移植物22.0岁。
- 终点为无菌性翻修,暴露为移植物类型及同种异体移植物处理方式,分析调整年龄、性别和种族,采用Kaplan-Meier曲线和Cox比例风险模型。
主要发现
- 粗未调整翻修率:骨-髌腱-骨自体移植物85例(1.9%),腘绳肌自体移植物132例(2.3%),软组织同种异体移植物83例(2.2%)。
- 与腘绳肌自体移植物相比,≥1.8 Mrad无化学处理同种异体移植物2.5年后翻修风险更高(HR 3.88;95%CI 1.48-10.12),≥1.8 Mrad有化学处理1年后更高(HR 3.43;95%CI 1.58-7.47),BioCleanse处理移植物任意时间点更高(HR 3.02;95%CI 1.40-6.50)。
- 与腘绳肌自体移植物相比,未处理同种异体移植物及<1.8 Mrad辐照(含或不含化学处理)移植物翻修风险无差异。
- 与骨-髌腱-骨自体移植物相比,腘绳肌自体移植物翻修风险更高(HR 1.51;95%CI 1.15-1.99),BioCleanse处理同种异体移植物更高(HR 4.67;95%CI 2.15-10.16)。
- 与骨-髌腱-骨自体移植物相比,<1.8 Mrad有化学处理(Allowash或AlloTrue)同种异体移植物翻修风险更高(HR 2.19;95%CI 1.42-3.38),<1.8 Mrad无化学处理更高(HR 2.31;95%CI 1.40-3.82),≥1.8 Mrad无化学处理2年后更高(HR 6.30;95%CI 3.18-12.48),≥1.8 Mrad有化学处理(Allowash或AlloTrue)1年后更高(HR 5.03;95%CI 2.30-11.00);未处理同种异体移植物与自体移植物相比翻修风险未增高。
关键数值与推荐
- 与腘绳肌自体移植物相比,≥1.8 Mrad无化学处理同种异体移植物2.5年后翻修风险HR 3.88(95%CI 1.48-10.12)。
- 与腘绳肌自体移植物相比,≥1.8 Mrad有化学处理同种异体移植物1年后翻修风险HR 3.43(95%CI 1.58-7.47)。
- 与腘绳肌自体移植物相比,BioCleanse处理同种异体移植物任意时间点翻修风险HR 3.02(95%CI 1.40-6.50)。
- 与骨-髌腱-骨自体移植物相比,腘绳肌自体移植物翻修风险HR 1.51(95%CI 1.15-1.99),BioCleanse处理同种异体移植物HR 4.67(95%CI 2.15-10.16)。
- 现有例数下无法对特定同种异体移植物处理方式之间进行直接比较。
临床怎么用
- 外科医生和患者需知晓前交叉韧带重建所用各种软组织同种异体移植物的翻修风险增加。
局限性
- 现有例数下无法对特定同种异体移植物处理方式之间进行直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal graft for anterior cruciate ligament reconstruction (ACLR) remains controversial. PURPOSE: To compare the risk of aseptic revision between bone-patellar tendon-bone (BPTB) autografts, hamstring autografts, and soft tissue allografts. STUDY DESIGN: Cohort study; Level of evidence, 2. METHODS: Prospectively collected ACLR cases reconstructed with BPTB autografts, hamstring autografts, and soft tissue allografts were identified using the Kaiser Permanente ACLR Registry. Aseptic revision was the endpoint. The type of graft and allograft processing method (nonprocessed, <1.8-Mrad irradiation with and without chemical processing [Allowash or AlloTrue], ≥1.8-Mrad irradiation with and without chemical processing, and chemical processing alone [BioCleanse]) were the exposures evaluated. Analyses were adjusted for age, sex, and race. Kaplan-Meier curves and Cox proportional hazards models were employed. RESULTS: The cohort included 14,015 cases: there were 8924 (63.7%) male patients, there were 6397 (45.6%) white patients, 4557 (32.5%) ACLRs used BPTB autografts, 3751 ACLRs (26.8%) used soft tissue allografts, and 5707 (40.7%) ACLRs used hamstring autografts. The median age was 34.6 years for soft tissue allografts, 24.3 years for hamstring autografts, and 22.0 years for BPTB autografts. The crude nonadjusted revision rates were 85 (1.9%) in BPTB autograft cases, 132 (2.3%) in hamstring autograft cases, and 83 (2.2%) in soft tissue allograft cases. After adjusting for age, sex, and race, compared with hamstring autografts, a higher risk of revision was found with allografts with ≥1.8 Mrad without chemical processing after 2.5 years (hazard ratio [HR], 3.88; 95% CI, 1.48-10.12) and ≥1.8 Mrad with chemical processing after 1 year (HR, 3.43; 95% CI, 1.58-7.47) and with BioCleanse processed grafts at any time point (HR, 3.02; 95% CI, 1.40-6.50). Nonprocessed allografts and those irradiated with <1.8 Mrad with or without chemical processing were not found to have a different risk of revision compared with hamstring autografts. Compared with BPTB autografts, a higher risk of revision was seen with hamstring autografts (HR, 1.51; 95% CI, 1.15-1.99) and BioCleanse processed allografts (HR, 4.67; 95% CI, 2.15-10.16). Allografts irradiated with <1.8 Mrad with chemical processing (Allowash or AlloTrue) (HR, 2.19; 95% CI, 1.42-3.38) and without chemical processing (HR, 2.31; 95% CI, 1.40-3.82) had a higher risk of revision, as did allografts with ≥1.8 Mrad without chemical processing after 2 years (HR, 6.30; 95% CI, 3.18-12.48) and ≥1.8 Mrad with chemical processing (Allowash or AlloTrue) after 1 year (HR, 5.03; 95% CI, 2.30-11.00) compared with BPTB autografts. Nonprocessed allografts did not have a higher risk of revision compared with autografts. With the numbers available, direct comparisons between the specific allograft processing methods were not possible. CONCLUSION: When soft tissue allografts are used for ACLR, processing and time from surgery affect the risk of revision. Tissue processing has a significant effect on the risk of revision surgery, which is most profound with more highly processed grafts and increases with increasing follow-up time. Surgeons and patients need to be aware of the increased risks of revision with the various soft tissue allografts used for ACLR.
引用
- Maletis GB, Chen J, Inacio MCS, et al. Increased Risk of Revision After Anterior Cruciate Ligament Reconstruction With Soft Tissue Allografts Compared With Autografts: Graft Processing and Time Make a Difference. Am J Sports Med. 2017. PMID: 28301224. doi:10.1177/0363546517694354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。